Interview with Ralf Dahmen, Managing Director, Galderma
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
Address: PO Box 196 Hawthorn Victoria 3122
Tel: (03) 8823 7333
Web: http://www.servier.com.au/home/default.asp
In just over 20 years, turnover has increased from $1 million in 1984 to $107 million for 2009. The number of people employed has risen steadily. The Sales force has grown from 6 representatives in 1984 spread across all Australian regions to in excess of 120 representatives today, but has maintained its reputation throughout this time as being amongst one of the best trained, most professional and most productive in Australia.
Servier’s activities in Australia commenced in 1979 with the launch of the anti-diabetic agent- Diamicron
Pivotal development work for the group’s flagship product Coversyl, which led to more than 30 publications from Australian researchers prior to marketing approval, culminated with the launch of Coversyl 2mg and 4mg in 1992.
In 1999 The International Centre for Therapeutic Research was established in Australia- The first outside of Europe and now has a staff in excess of 30 involved in phase l,ll and lll clinical research.
By January 1999 the company had outgrown it’s head office of 15 years and moved to it’s new purpose built office in Hawthorn, Melbourne, which saw the divisions of Sales/Marketing and Research all housed under the one roof.
Coversyl 8mg was launched in February 2004 and already contributes 21% of the Company annual turnover.
Coralan, a new treatment for chronic stable angina was registered in November 2006.
In April 2007, Protos, a new treatment for post menopausal osteoporosis was listed on the PBS.
Servier Australia is the local subsidiary of Servier, a leading French research-based pharmaceutical entity, specialising in ethical pharmaceuticals. Employing over 200 people in Australia, its headquarters are in Hawthorn, Melbourne. In 2009 Servier Australia had an annual turnover of $107 million.
Servier Laboratories Limited comprises two principal divisions:
Clinical Research
The management of phase l, ll, lll and lV clinical trials in collaboration with research-based hospitals and general practices throughout Australia.
Sales and Marketing
Sales and Marketing deliver Servier’s portfolio of ethical pharmaceutical products to primary and secondary healthcare professionals
In addition to a team of representatives throughout Australia, to support the operational activities of the above divisions, there is naturally a complete range of professional support functions that include the following: Training, Medical Information (Marketing), Regulatory Affairs, Human Resources, Finance, Information Services, Strategic Coordination, External and Government Relations and Medical Affairs.
Servier Australia offers a range of products in a number of medical areas: cardiovascular disease, especially hypertension and cardiac disease, diabetes and more recently osteoporosis
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
See our Cookie Privacy Policy Here
